Home  |  Search:
Home > News & Events

FreeMind 7th Annual Non Dilutive Funding Day

FreeMind Group's 7th Annual
Non Dilutive Funding Day
During the JP Morgan HealthCare Conference
Wednesday, January 11, 2012, The Nikko Hotel,San Francisco
 
8:00 - 10:00:
Non-Dilutive Funding Forecast

8:00 – 9:00: Breakfast and Networking
9:00 - 10:00: "NIH/DOD 2012 Forecast - Current RFAs & RFPs"
Mr. Ram May-Ron, Managing Partner, FreeMind Group
Merav Geva, Ph.D, Chief Analyst & Director of Professional Services, FreeMind Group


10:15 - 1:45: 
Round Table Discussions:
Merav Geva, Ph.D, Chief Analyst & Director of Professional Services, FreeMind Group

10:15 AM - Translational Research
11:00 AM - Devices and Technology Development (Platform Technology)
11:45 AM - Industry-Academia partnerships
 1:00 PM - DoD and related agencies

2:30 - 3:30:
"Private Foundation Funding" Panel
Moderator - Mr. Ram May-Ron, Managing Partner, FreeMind Group
Speakers –
Michael J. Fox Foundation
Juvenile Diabetes Research Foundation International (JDRF)
American Heart Association
 
This event is FREE of charge.
 
To schedule 1X1 meeting with the FreeMind team please contact Hannah Rosencweig at (617)648-0340  ext. 220 hannah@freemindconsultants.com
 
 
Event Sponsors:

Beyond VCs and Wall Street at the Life Science Summit

Life Science Summit 2011
Wednesday, November 16th at 11:15-12:10pm
During the Life Science Summit 2011 (www.lifesciencessummit.org) FreeMind Group will moderate a Business Workshop on:
Beyond VCs and Wall Street: "The role of government agencies and foundation as fuel to the Life Science R&D engine"
Today the financial world supporting life science research and development efforts is at a standstill. On the one hand the VC model has proven incapable of supporting the needs of the market and industry alone and on the other big pharma's and the public market as well as angel investor have not proven themselves capable of stepping in and covering the gap. To many this is spelled "Valley of Death". Non-diluting funding represent a possible alternative and a definite complementary source of funding aimed at supporting R&D and possibly could assist the industry to lay a bridge over the valley.

Moderator:
·                                 Ram May-Ron, Managing Partner, FreeMind Group

Panelists:
  • Jonathan J. Fleming, Managing General Partner, Oxford Bioscience Partners
  • Sharon E. Semones, Portfolio Consultant, Global External Research and Development, Eli Lilly
  • Lance Stewart PhD, Chief Executive Officer, Emerald BioStructures
  • Michael G Kurilla, MD-PhD, Director, Office of BioDefense Research Affairs
    Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS
  • Barry Wolitzky, PhD, Executive Director of Strategic Partnering, Immune Tolerance Network

NIH and DoD strategic funding opportunities for academia industry and their collaborations

FreeMind Group and the Fred Hutchinson Cancer Research Center
are pleased to invite you to an educational seminar focusing on
Non dilutive funding mechanisms and the process of maximizing chances for awards on complex and large scale applications
 
Presenter:
Ayal Ronen, Senior Director Marketing & Sales, FreeMind Group

While the NIH budget is only moderately affected by recent financial and economic events, we are witnessing continued movement towards larger scope and collaborative awards, and an increased competitiveness on standard awards as the number of submissions grows dramatically.

This competitive environment calls for adjustments from veteran researchers, as well as a better preparation and understanding of the funding mechanisms, systems and interests that lead to award.
The challenge today therefore is to identify the most suitable funding opportunity for a specific project, while presenting a clear and coherent application relating to all aspects that are reviewed: scientific, financial and strategic. 
In this seminar we will discuss:
  • Government funding as a strategic source of funding
  • Identifying the most relevant funding opportunities and how to set your application's strategy
  • Industry & academia collaboration
  • The challenges in putting together a complex and large scale application
  • Short term/large scale funding opportunities 
  • Process for applying, requirements and limitations
  • How to maximize chances for success
The seminar is designed for new and experienced researchers from academic research institutes, and for life science companies conducting R&D activities, who wish to increase their chances for as well as the total amount of funding awarded. 

The seminar is FREE of charge.
Monday, November 14th at 2:00 PM-3:00 PM PDT
Fred Hutchinson Cancer Research Center
Pelton Auditorium (B1-065), the Thomas Building
1100 Fairview Ave. N. J5-110, Seattle, WA  98109-1024
 
To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com
 

 

Biotech 2011: Imagine. Collaborate. Innovate

Biotech 2011: Imagine. Collaborate. Innovate

October 24-25
Pennsylvania Convention Center, Philadelphia

Join top bioscience leaders from around the world to network, connect with potential partners, share business strategies, and learn from their peers.
Of special interest is our new Innovation Forum which kicks off with a Funding Roundtable Luncheon, Company Showcase and Innovation Corridor.
For more information and details visit the website: Biotech2011.org.

Ram May-Ron, FreeMind's Managing Partner, will hold a "Funding Roundtable Lunch and Innovation Forum" on October 25th at 12:00 p.m. - 3:30 p.m. at Ballroom B

 

SBIR/STTR Programs - The Gateway to Life Science Industry Non-Dilutive Funding

We are happy to accommodate requests for a re-broadcast of the following webinar:

FreeMind Group is pleased to invite you to our 10th webinar in a series of summer educational webinars focusing on the SBIR/STTR opportunities

 
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Oftentimes, the SBIR/STTR programs are a necessary step that BioTech and Medical Device companies take in order to display their strengths and graduate to become prime candidates for large scale awards in the millions of dollars. Despite the fierce competition and seemingly limiting factors, if properly approached and neatly executed, this program may prove to be a substantial source of funding complementary to traditional sources. To meet these challenges, and to turn out a top quality application, it is more important than ever to understand the intricate requirements of the SBIR/STTR program, thus maximizing your chances for award.
In this webinar we will discuss:
  • SBIR/STTR regulations.
  • Leveraging your SBIR/STTR money to large scale funding opportunities. 
  • Industry & academia collaboration
  • Process for applying, requirements and limitations
  • How to maximize chances for success
  • Government funding as a strategic source of funding
 
The webinar is designed for experienced companies, as well as for first-time submitters, and researchers from the Academia who wish to increase their chances for award, as well as the total amount of funding awarded. 
Tuesday, September 6th at 1:00 PM-1:30 PM EDT
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 221, or at Hannah@freemindconsultants.com


Medical Device Non-Dilutive Funding: Trends & Opportunities

FreeMind Group is pleased to invite you to our 9th webinar in a
series of summer educational webinars focusing on non-dilutive
funding for medical devices

Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

 

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In this webinar we will present the latest trends at the NIH and the new available funding opportunities with respect to medical devices.    
 In this webinar we will discuss:
  • Trends in medical device non-dilutive funding
  • Cross section analysis of different opportunities available
  • The NIBIB – The national institute of Biomedical Imaging and Bioengineering
  • Challenges
  • How to maximize chances for success
When:
Tuesday, August 30th at 1:00-1:30 PM EDT

The webinar is designed for experienced companies and researches from the academia, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge.
To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

Details of a Detailed Budget

FreeMind Group is pleased to invite you to our 8th webinar in a series of summer educational webinars focusing on how to accurately construct your budget while adhering to NIH guidelines
 
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Putting together a budget for your grant submission is typically the last item to be addressed during the writing process. Reason being that the figures you are suggesting must reflect the work you are proposing to complete. That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of your budget. When comprising the budget one must ensure an accurate completion of the document while adhering to NIH guidelines and stipulations. Items such as indirect costs, sub-contractors, sub-awards, salaries, and even travel expenses must be completed correctly. This becomes increasingly difficult when large and complex applications have several budgets feeding into one.
In this webinar we will discuss:
  • Budget: Know the limits
  • Direct vs. Indirect
  • Facilities & Administration rate
  • Modular or detailed: which to use?
  • Allowable costs
  • Final tips
 When:
Tuesday, August 23rd at 1:00-1:30 PM EDT

The webinar is designed for experienced companies and researches from the academia, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

Details of a Detailed Budget

DOD Funding Opportunities for Life Science Research

FreeMind Group is pleased to invite you to our 7th webinar in a series of summer educational webinars focusing on DOD non-dilutive funding
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Navigating one's way around the numerous available funding opportunities within the Department of Defense (DoD) can be a daunting task, which sometimes leads to misperceptions about the submission process and the prospects for getting funded.  Since all of its agencies are highly mission-oriented, understanding the basic structure and focus of each agency within DoD is absolutely critical for a successful outcome.
How is DoD funding categorized? How is funding announced? How are funding decisions being made?  In the upcoming webinar we will give an overview of the major programs available through the DoD and discuss the key points in the process and in particular:
Department of Defense – DARPA, DTRA, TMT, CDMRP
  • CDMRP Research Programs
  • The Key to Understanding DARPA
  •  Meeting the mission of DTRA
  • Immediate funding opportunities
  • Government funding as a strategic source of funding
When:
Tuesday, August 16th at 1:00-1:30 PM EDT

The webinar is designed for experienced companies and researches from the academia, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

R Mechanisms for Companies

FreeMind Group is pleased to invite you to FreeMind's 6th webinar in a series of summer educational webinars.
This Webinar will discuss the differences between R' mechanisms and the path to non-dilutive funding
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Navigating your way around the numerous available funding mechanisms within the NIH can be challenging especially as the multiple NIH mechanisms are designed to address different stages of your R&D work. One can also breakdown the science into more focused applications targeting different institutes while utilizing alternative mechanisms. In fact, this part of any strategic assessment is the first stage and is of high importance in leading to a favorable outcome when targeting government funding.
Mechanisms differ by scope, eligibility, budget, basic objectives, grant sections and more.
We will give an overview on R mechanisms and present some available solicitation from each mechanism.
In this webinar we will discuss:
  • Different types of R' mechanism (RO1, R21, R33 etc.)
  • Target the Right Mechanism
  • R-Series NIH funding opportunities
  • Awards, regulations, applying, requirements and limitations
  •  How to maximize chances for success
When:
Tuesday, August 9th at 1:00-1:30 PM EDT

The webinar is designed for experienced companies as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

Non-Dilutive Funding for Industry-Academia Partnerships

FreeMind Group is pleased to invite you to FreeMind's 5th webinar in a series of summer educational webinars.
This Webinar will discuss the importance of Industry-Academia Research Partnerships and paths to funding through non-dilutive sources
 
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Industry-academia partnerships drive the life science market forward and the importance of sustaining and nurturing these relationships is high on the agenda of both industry and academic leaders. Over the past several years we are witnessing a changing direction at the NIH and other government granting agencies aimed at supporting these relationships.
This new direction, according to NIH Director Francis Collins, stems from the realization that the medical benefits of the current revolution in biology clearly cannot be achieved without vigorous and effective translation. This leads to a strong need for collaboration and partnering between the industrial sector and academia, which is also well reflected in the numerous grant programs supporting industry-academia collaborations and partnerships.
We will give an overview to the opportunities available for funding your industry-academia collaborations, using non-dilutive government funding.
In this webinar we will discuss:
  • Current Partnership Funding Opportunities
  •  Awards, regulations applying, requirements and limitations
  • Trends in Academic-Industry Collaborations
  • New Direction at the NIH
  • The challenges in putting together a complex and large scale application
  • How to maximize chances for success

When:
Tuesday, August 2nd at 1:00-1:30 PM EDT

The webinar is designed for experienced companies and researches from the academia, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

CNS & Parkinson's Research Funding Opportunities

FreeMind Group & The Michael J. Fox Foundation are pleased to invite you to FreeMind's 4th webinar in a series of summer educational webinars.
This Webinar will be focusing on CNS &Parkinson's research non-dilutive funding
Presenters:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group
Tracey Mumford, Associate Director, Research Partnerships , The Michael J. Fox Foundation for Parkinson's Research
1.      CNS diseases and Parkinson's in particular are highly variable diseases and complex research objectives. As such, this field of research is targeted by several non-dilutive funding agencies, both private and federal. The Michael J. Fox Foundation (MJFF) is dedicated to delivering better treatments and, ultimately, a cure for Parkinson's disease. MJFF prioritizes research with the most promise for improving diagnosis and treatment.
MJFF - the largest private funder of Parkinson's research - awarded almost $50M in new grants in 2010. Over the past 10 years, the Foundation has funded over $250M in Parkinson's research. Other sources, like NIH, invest greatly in better understanding the causes and providing possible solutions to patients.
For over 12 years FreeMind Group (FMG) is the leading consulting firm on non-dilutive funding. Many of the projects for which FMG has assisted its clients focus on CNS in general and Parkinson's in particular. FMG's work supports research conducted within industry and academia and assists its clients to receive funding from Federal and private foundations alike. Recently, FMG and MJFF have joined forces in an attempt to further the financial support received by researchers in the field.

In this webinar we will discuss:
§         Upcoming program deadlines
§         Awards, regulations applying, requirements and limitations
§         MJFF Priority Focus Areas
§         CNS & Parkinson's Research Funding Opportunities from different mechanisms
§         The challenges in putting together a complex and large scale application
§         How to maximize chances for success
§         Industry & academia collaboration
When:
Tuesday, July 26th at 1:00-1:30 PM EDT

The webinar is designed for experienced companies and researches from the academia, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 

The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com

 

 

NIH/DOD Funding Opportunities for Life Science Companies

FreeMind Group is pleased to invite you to our 3rd webinar in a series of summer educational webinars focusing on NIH/DODnon-dilutive funding
 

Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

We are witnessing a continuous movement by the NIH and DOD towards the life science industry, with a greater understanding as to the industry's needs, focus, and challenges. The scope of funding support given to industry R&D efforts from non-dilutive sources such as NIH and DOD covers the entire R&D cycle from early stage exploratory activities and all the way to late stage clinical research activities (Phase I, and II).
All non-dilutive sources are now expressing greater than ever interest in the R&D efforts of the industry, and more so in the unique set of skills and assets presented by collaborative academia-industry alliances. In the presentation we will discuss the latest trends at the NIH and DOD and the new available large scale and clinical stage funding opportunities.

In this webinar we will discuss:
§         The challenges in putting together a complex and large scale application
§         Short term/large scale funding opportunities 
  • Process for applying, requirements and limitations

§         How to maximize chances for success
§         Industry & academia collaboration
§         Government funding as a strategic source of funding
When:
Tuesday, July 19th at 1:00-1:30 PM EDT

The webinar is designed for experienced companies, as well as for first-time submitters who wish to increase their chances for award, as well as the total amount of funding awarded. 
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 221, or at Hannah@freemindconsultants.com
 

 

SBIR/STTR Programs

SBIR/STTR Programs - The Gateway to
Life Science Industry Non-Dilutive Funding


FreeMind Group is pleased to invite you to a special Webinar to present the SBIR/STTR opportunities

 
Presenter:
Ayal Ronen, Senior Director, Marketing & Sales, FreeMind Group

Oftentimes, the SBIR/STTR programs are a necessary step that BioTech and Medical Device companies take in order to display their strengths and graduate to become prime candidates for large scale awards in the millions of dollars. Despite the fierce competition and seemingly limiting factors, if properly approached and neatly executed, this program may prove to be a substantial source of funding complementary to traditional sources. To meet these challenges, and to turn out a top quality application, it is more important than ever to understand the intricate requirements of the SBIR/STTR program, thus maximizing your chances for award.
In this webinar we will discuss:
  • SBIR/STTR regulations.
  • Leveraging your SBIR/STTR money to large scale funding opportunities. 
  • Industry & academia collaboration
  • Process for applying, requirements and limitations
  • How to maximize chances for success
  • Government funding as a strategic source of funding
 
The webinar is designed for experienced companies, as well as for first-time submitters, and researchers from the Academia who wish to increase their chances for award, as well as the total amount of funding awarded. 
Tuesday, July 5th at 1:00 PM-1:30 PM EDT
The webinar is FREE of charge. To register, please contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at Hannah@freemindconsultants.com



Meet The FreeMind team at the BIO International Convention

June 27-30, 2011
This year at the 2011 BIO International Convention on June 27-30, 2011 - Walter E. Washington Convention Center Washington, DC,  the FreeMind team will be holding strategic consultations with industry executives discussing specific projects.

To schedule a meeting with:
Mr. Ram May-Ron, Managing Partner
Dr. Orna Harel, Senior Analyst
Mr. Ayal Ronen, Senior Director Marketing & Sales
Mr. Mark Fireman, Director of Business Development

Please contact us at contact at (617) 648-0340  or at casey@freemindconsultants.com
 

The 13th Annual C21 BioVentures conference

FreeMind Group is proud to be a media sponsor of the 13th Annual C21 BioVentures™ conference, which will be held May 24-26, 2011 at the Meritage Resort in Napa, California.
 
Mr. Ram May-Ron, FreeMind's Managing Partner and Mr. Ayal Ronen FreeMind's Senior Director, Marketing and Sales, will be holding 1X1 meetings during the conference and will discuss the dozen funding opportunities covering virtually all aspects of infectious diseases in biodefesne for the May, June and July deadlines, including medical devices, preclinical, and clinical work, to name a few. Applications will be submitted corresponding to about $500,000,000 in subsequent cumulative awards and other funding opportunities.

BioNJ's Second Annual International BioPartnering Conference

 

 

Ram May-Ron, FreeMind's Managing Partner is invited to speak at the BioNJ's Second Annual International BioPartnering Conference - May 23 – 24, 2011 at the Westin Princeton at Forrestal Village.

The Plenary Session will take place on May 24th at 8:30 am
“Non-Dilutive Funding as a Step Toward Validation Panel”

Brenda Gavin, Founding Partner
Quaker BioVentures, Moderator

Ram May-Ron, Managing Partner
FreeMind Group

Scott T. Megaffin, Senior Vice President, Commercial
Onconova Therapeutics Inc.

Richard Winneker, Ph.D., Senior Vice President, Research
The Leukemia & Lymphoma Society


Mr. May Ron will hold 1X1 during the conference. For more information please visit BioNJ's website at: http://www.bionj.org/news/2011-international-biopartnering-conference

UIDP - Pfizer Meeting

FreeMind's Managing Partner Mr. Ram May-Ron is invited to speak at the UIDP - Pfizer Meeting on  Financing Industry ‐ Academia Collaborations through Non‐Dilutive Funding Resources

April 4-6, 20011

The presentation will discuss current trends for R&D from non‐dilutive funding sources for Industry & Academia ‐ both within and outside NIH and large scale funding programs.‐clinical and clinical research and development activities and the criteria for award. We will discuss the process of identifying funding opportunities that are relevant and what it takes to manage and complete the writing process of the applications.

Available opportunities, the funding of pre
We will discuss current trends of non‐dilutive funding sources and their affect on Academia‐Industry collaborations as well as the possibility of Financing Industry ‐Academia Collaborations through Non‐Dilutive Funding Resources.

Partnerships for Biodefense (R01)

FreeMind Group is pleased to invite you to
 a special webinar focusing on the latest announcement of the NIAID program, Partnerships for Biodefense (R01)
May 27, 2011 Deadline
 
Presenters: Ayal Ronen, MSc. Senior Director of Marketing and Sales,
FreeMind Group LLC

When:
Wednesday, March 23rd at 13:30-2:30 PM EST

Funding is available from various governments' sources to support R&D efforts for Biodefense, ranging from the very beginning of exploratory research and all the way to final stage clinical testing.
 
The purpose in this specific opportunity is to support preclinical development of lead candidate vaccines, therapeutics, adjuvants or diagnostics against NIAID Category A, B, or C priority agents. 
Up to $750,000 per year for a maximum period of 5 years.
In addition, up to a total of $300,000 for major equipment in the first year of the award.

Topics to be discussed:
  • A detailed discussion of "Partnerships for Biodefense (R01)"
  •  Other Funding opportunities for Biodefense R&D
  • Application process, requirements and limitations
  • The differences between the requirements of different agencies and mechanisms 
  • Industry–Academia collaboration
 
This event is free of charge; however an early registration is required.

Please contact Hannah Rosencweig at Hannah@freemindconsultants.com to register

 

WBBA - 11th Annual Life Science Innovation Northwest Conference


Meet FreeMind's Managing Partner Mr. Ram May-Ron at the 11th Annual Life Science Innovation Northwest Conference to discuss "NIH/DOD 2011 Forecast - Current RFAs & RFPs"
The meeting will take place on Wednesday, March 2 – Thursday, March 3, 2011 at The Washington State Convention Center (http://washbio.org/displaycommon.cfm?an=1&subarticlenbr=145)

For more information please contact Casey Levin at: casey@freemindconsultants.com or at : (617) 648-0340 ext. 216

 

Lunch and Learn at the San Jose BioCenter

FreeMind Group and the San Jose BioCenter are pleased to invite you to a
special "Lunch & Learn" event focusing on non-dilutive funding for industry
 
Presenter: Ram May-Ron, Managing Partner, FreeMind Group

The presentation will discuss current trends for R&D non-dilutive funding sources for industry both within and outside NIH and the SBIR program, available opportunities, the funding of pre-clinical and clinical research and development activities and the criteria for award. We will discuss the process of identifying funding opportunities that are relevant and what it takes to manage and complete the writing process of the applications.
 
The presentation will be followed by 1X1 meetings to discuss specific projects.
 
This event is free of charge.
 
For more information and registration please contact Casey Levin at casey@freemindconsultants.com , (617) 648-0340 ext. 216

BIOCOM's Global Life Science Partnering Conference


Meet FreeMind's Managing Partner Mr. Ram May-Ron at the BIOCOM's Global Life Science Partnering Conference to discuss "NIH/DOD 2011 Forecast - Current RFAs & RFPs"
The meeting will take place on Wednesday, February 23, 2011 - Thursday, February 24, 2011, La Jolla, CA

For more information please contact Casey Levin at: casey@freemindconsultants.com or at : (617) 648-0340 ext. 216
 

FreeMind's 6th Annual Non-Dilutive Funding Day

during the JP Morgan HealthCare Conference

Wednesday, January 12, 2011, The Nikko Hotel, San Francisco

8:00 - 10:00:
Non-Dilutive Funding Forecast

8:00 - 9:00: Breakfast and Networking

9:00 - 10:00: "NIH/DOD 2011 Forecast - Current RFAs & RFPs"
Mr. Ram May-Ron, Managing Partner, FreeMind Group
Merav Geva, Ph.D, Chief Analyst & Director of Professional Services, FreeMind Group

10:15 - 3:30:
Round Table Discussions:
Merav Geva, Ph.D, Chief Analyst & Director of Professional Services, FreeMind Group

10:15 am - Personalized medicine, biomarkers & diagnostics
11:00 am - Medical devices
11:45 am - Neurodegenerative diseases 
  1:00 pm - Infectious diseases and biodefense
  2:00 pm - Inflammatory diseases
  3:00 pm - Translational and clinical studies

10:00 - 4:00:
1X1 with FreeMind's Team


4:00pm - 5:00pm:
Grant on the Rocks
An afternoon cocktail reception
This event is FREE of charge.
To register and/or to schedule 1x1 meeting, please contact Casey Levin: 617 648-0340 ext. 216 casey@freemindconsultants.com  

 
Sponsors:

BioNJ - www.BioNJ.org
AdvaMed - www.advamed.org

BioHouston - www.biohouston.org
BioFlorida - www.bioflorida.com
Georgia Bio (GaBio) - www.gabio.org

Indiana Health Industry Forum (IHIF) - www.ihif.org
Kansas Bioscience Organization (KansasBio) - www.kansasbio.org

North Carolina Biosciences Organization (NCBIO) - www.ncbioscience.org

Washington Biotechnology & Biomedical Association

(WBBA) -  www.washbio.org 

webinar: Non-Dilutive Funding for Medical Device Companies

Medical Device Non-Dilutive Funding:
Trends & Opportunities
 
FreeMind Group is pleased to invite you to a
special webinar focusing on medical device non-dilutive funding
Presenters: Guy Harchen, MSc. Grants Consultant
Department of Professional Services, FreeMind Group LLC

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In this webinar we will present the latest trends at the NIH and the new available funding opportunities.    
 In particular we will discuss :

  • Trends in medical device non-dilutive funding.
  • Cross section analysis of different opportunities available.
  • Industry & academia collaboration.
  • Process for applying, requirements and limitations.
  • How to maximize chances for success.
  • Government funding as a strategic source of funding
When:
Thursday, October 7th at 1:00-2:00 PM EDT

This Webinar is FREE of charge.

To register please contact: Casey Levin at casey@freemindconsultants.com or at (617) 648-0340 ext. 216
 

Sponsors:

LifeScience Alley®  - www.lifesciencealleyconference.org

AdvaMed- www.advamed.org

 

FreeMind presentation at the UIDP Meeting

Large Scale Grants & Contracts for Life Science Companies & Academia

FreeMind Group and The National Academies – UIDP are pleased to invite you to a
special presentation and 1X1 meetings focusing on large scale non-dilutive funding during the upcoming UIDP Fall Conference, October 4th, 2010
Presenters: Ram May-Ron, Managing Partner, FreeMind Group LLC

We are witnessing today a continuous movement by the NIH and DOD towards the life science industry, with a greater understanding as to the industry's needs, focus, and difficulties. The scope of funding support given to industry R&D efforts from non-dilutive sources such as NIH and DOD covers the entire R&D cycle from early stage exploratory activities and all the way to late stage clinical research activities (Phase I, II and II). All non-dilutive sources are now expressing greater than ever interest in the R&D efforts of the industry, and more so in the unique set of skills and assets presented by collaborative academia-industry alliances. In the presentation we will discuss the latest trends at the NIH and DOD and the new available large scale and clinical stage funding opportunities.

In this presentation we will discuss in particular:
  • The challenges in putting together a complex and large scale application
  • Short term/large scale funding opportunities 
  • Process for applying, requirements and limitations
  • How to maximize chances for success
  • Industry & academia collaboration
  • New clinical funding opportunities
  • Government funding as a strategic source of funding
When:
Monday, October 4th at 1:00-2:00 PM EDT
The presentation will be followed by 1X1 meetings to discuss specific projects
Location:
University of North Carolina at Charlotte
9201 University City Blvd, Charlotte, NC 28223-0001
GRIGG 132 Room
 
This event is FREE of charge.

To register, and/or to schedule 1X1 meetings please contact:
Hanna Rosensweig at Hannah@freemindconsultants.com or at (617) 648-0340 ext. 221

Non-Dilutive Funding for Biodefense & Infectious Diseases Clinical Research


FreeMind Group is pleased to invite you to anexclusive presentation, discussion and 1x1 meetings focusing on the upcoming Broad Agency Announcement (BAA) for “Development of therapeutics for Biodefense“during the Rodman & Renshaw 12th annual Healthcare Conference, NYC, NY


Presenter: Ram May-Ron, Managing Partner, FreeMind Group LLC
In this presentation we will discuss:
 
  • The upcoming Broad Agency Announcement (BAA) for “Development of therapeutics for Biodefense“- with a per project budget of up to $17 million.
  • NIAID – Other Funding opportunities for Biodefense R&D.
  • DOD and TMT funding opportunities
  • Industry & academia collaboration
  • Application process, requirements and limitations, and the differences between the requirements of different agencies and mechanisms 
  • How to maximize chances for success
  •  The challenges in putting together a complex and large scale application
 
When:
Wednesday, September 14th at 8:30-9:15 AM EDT
The presentation will be followed 1X1 meetings to discuss specific projects
Location:
The New York Palace Hotel
455 Madison Avenue
New York, NY 10022
 
This event is FREE of charge.
To register, and/or to schedule 1X1 meetings please contact:Hannah Rosencweig at Hannah@freemindconsultants.com  (617) 648-0340 ext. 220
 

Non-Dilutive Funding Brief & Relaxed Cocktail Reception

Grants on the Rocks
 

Monday, Sept 13, 5-7pm, The Waldorf=Astoria, NYC during the Rodman & Renshaw 12th annual Healthcare Conference

 FreeMind Group, in conjunction with six of the leading states Biotech organizations, is pleased to invite you to a special non-dilutive funding event.  

 In this presentation we will discuss:
  •  Strategies for securing late stage funding from non-dilutive sources
  •  Currently available large scale funding opportunities, including clinical stage activities
  •  Process for applying, requirements and limitations
  • The challenges in putting together a complex and large scale application
  • How to maximize chances for success
  •  Industry & academia collaboration
 
4:30-5:00 pm - Presentation; Ram May-Ron, FreeMind Group's Managing Partner
5:00 - 6:00 pm - Cocktail Reception

The Waldorf=Astoria
Peacock Alley West Room
301 Park Avenue
New York, NY 10022
 
This event is FREE of charge however, space is limited.
To register, and/or to schedule 1X1 meetings please contact: Hannah Rosencweig at Hannah@freemindconsultants.com  (617) 648-0340 ext. 220
 
This presentation is sponsored by:
·                                                                                                                                                                                                                                                              BioFlorida - www.bioflorida.com
·                                                                                                                                                                                                                                                              Georgia Bio - www.gabio.org
·                                                                                                                                                                                                                                                              Indiana (IHIF) - www.ihif.org
·                                                                                                                                                                                                                                                              Minnesota (LifeScience Alley) - www.lifesciencealley.org
·                                                                                                                                                                                                                                                              BioHouston - www.biohouston.org
·                                                                                                                                                                                                                                                              Washington (WBBA) - www.washbio.org

NIH/DOD New Funding Opportunities for the Vaccine & Bio-Defense Industry

 
 
Special 1x1 Meetings with FreeMind Group at CHI/ImmVacS, August 17-19
 

The Federal Agencies, mainly NIH and DOD, are moving towards the industry offering a wide range of funding opportunities from early stage research all the way to the later stages of clinical studies and up to Phase III. These alternative funding mechanisms have become of greater interest to both small size start ups and large scale and even big Pharma alike.  

FreeMind Group is the leading consulting firm that specializes in raising funds from non-dilutive sources. The enhanced joint process of our 25 full-time analysts and writers supports our clients' needs, from the strategic assessment of the research objectives to writing the applications. Over the past decade we have helped hundreds of companies and academic institutions to secure funding, mainly from the NIH and DOD. 

FreeMind's Managing Partner, Mr. Ram May-Ron will hold 1X1 meetings during the CHI ImmVacS conference to discuss these opportunities.


August 17-19, 2010
Royal Sonesta Hotel, Cambridge, MA.

To schedule a meeting please contact Hannah Rosencweig at hannah@freemindconsultants.com or at (617) 648-0340 ext. 221

Large Scale Grants & Contracts for Life Science Companies & Academia

 FreeMind Group and BIOHouston are pleased to invite you to a
special presentation and reception focusing on large scale non-dilutive funding

 Presenter: Ram May-Ron, Managing Partner, FreeMind Group LLC

 

 

We are witnessing today a continuous movement by the NIH and DOD towards the life science industry, with a greater understanding as to the industry's needs, focus, and difficulties. The scope of funding support given to industry R&D efforts from non-dilutive sources such as NIH and DOD covers the entire R&D cycle from early stage exploratory activities and all the way to late stage clinical research activities (Phase I, II and II). All non-dilutive sources are now expressing greater than ever interest in the R&D efforts of the industry, and more so in the unique set of skills and assets presented by collaborative academia-industry alliances. In the presentation we will discuss the latest trends at the NIH and DOD and the new available large scale and clinical stage funding opportunities.

In this presentation we will discuss in particular:

  • The challenges in putting together a complex and large scale application
  •  Short term/large scale funding opportunities 
  • Process for applying, requirements and limitations  How to maximize chances for success
  • Industry & academia collaboration
  • New clinical funding opportunities
  • Government funding as a strategic source of funding

When:
Tuesday, July 14th at 4:00-5:30 PM EDT
The presentation will be followed by 1X1 meetings to discuss specific projects

Location:
BIOHouston -
2555 Holly Hall
Suite 100
Houston, Texas 77054

This event is FREE of charge. To register, and/or to schedule 1X1 meetings please contact:

Sara Mathews at sara.mathews@biohouston.org

 

 

FreeMind Group and BIOHouston are pleased to invite you to a

special presentation and reception focusing on large scale non-dilutive funding

 

Presenter: Ram May-Ron, Managing Partner, FreeMind Group LLC

Meet FreeMind at the 2010 BIO International Convention

 May 3-6, 2010

At the 2010 BIO International Convention on May 3-6, 2010 at McCormick Place in Chicago, IL Mr. Ram May-Ron, VP of FreeMind Group will be holding strategic consultations with Industry Executives on 'NIH moves towards the industry' and discussions regarding specific projects with FreeMind's Chief Analyst, Dr. Merav Geva.
Schedule a meeting now or contact Casey Levin at (617) 648-0340 ext. 216 or at casey@freemindconsultants.com

Learn about the CAN initiative and about new funding levels for SBIR

April 14th 2010

FreeMind Group is pleased to invite you to a special webinar about:
CAN - The Cures Acceleration Network is a new clinical support initiative authorized as part of the Health Insurance Reform Bill, which will award grants to biotech companies, universities, and patient advocacy groups to support clinical research.
SBIR - Under the newly approved regulation SBIR funding has increased from $100K to $150K for an SBIR Phase I award; and from $750K to $1M for an SBIR Phase II award.

Presenter: Ram May-Ron, Vice President , FreeMind Group LLC

The webinar will take place on:

April 14th 2010 at 2:00 pm EDT

The webinar is FREE of charge.
Register Now or for further information please contact Casey Levin at (617) 648-0340, ext. 216 casey@freemindconsultants.com

FreeMind Group & Washington Biotechnology and Biomedical Association (WBBA)

March 18th 2010
 

Please join FreeMind Group's presentation about ' Large Scale Grants & Contracts for Research Institutes'
FreeMind Group and WBBA are pleased to invite you to a special presentation and discussion focusing on current federal funding trends for large scale opportunities and multi-disciplinary projects
Presenter: Ram May-Ron, VP FreeMind Group LLC
Thursday, March 18th at 9:00-10:00 AM. The presentation will be followed by 1X1 meetings to discuss specific projects.

Location:
The Bell Harbor International Conference Center Seattle,
the Marina meeting room
2211 Alaskan Way, Pier 66, Seattle, WA 98121

10th annual “Life Science Innovation Northwest” Conference

March 16-17 2010
 

At the 10th annual “Life Science Innovation Northwest” conference in Seattle, Washington on March 16-17 2010 Mr. Ram May-Ron, VP of FreeMind Group will be holding strategic consultations with Industry Executives on trends at the NIH and DOD in 2010 and discussions regarding specific projects.
All meetings will be held at the Bell Harbor International Conference Center.

To schedule a meeting please contact Casey Levin at casey@freemindconsultants.com or at (617) 648-0340 ext. 216

9th Annual BIO Windhover & Windhover Pharmaceutical Strategic Outlook

February 23-25, 2010

At the 9th Annual Bio-Windhover Conference 2010 in New York City on February 23-25, 2010 FreeMind Group representatives will be holding strategic consultations with Industry Executives on trends at the NIH and DOD in 2010 and discussions regarding specific projects.
All meetings will be held at the Grand Hyatt New York.

To schedule a meeting please contact Casey Levin at: casey@freemindconsultants.com or at (617) 648-0340 ext. 216

12th Annual BIO CEO & Investor Conference

February 8-9 2010

At the 10th annual “Life Science Innovation Northwest” conference in New York City on February 8-9 2010 Mr. Ram May-Ron, VP of FreeMind Group will be holding strategic consultations with Industry Executives on trends at the NIH and DOD in 2010 and discussions regarding specific projects.
All meetings will be held at the Waldorf-Astoria.

To schedule a meeting please contact Casey Levin at casey@freemindconsultants.com or at (617) 648-0340 ext. 216

Texas Life Science Conference, 2010

November 11-13, 2009

Freemind Group will be presenting at the "Texas Life Science Conference", about Grants, Stimulus Money and More! An overview on how to tap into federal funding resources available to entrepreneurial life science companies.

To register please visit BioHouston website at www.biohouston.org

 

TRANSPARENCY IN GOV’T. FUNDING OPTIONS FOR BIODEFENSE IS KEY TO SECURING PRIVATE EQUITY INVESTMENT IN SECTOR

January 13, 2010

FreeMind’s Public/Private Sector Roundtable Discusses Funding, Project Prioritization and Collaborative Research

In the wake of a decision last month to move more than $600 million from the nation’s Project Bioshield Special Reserve Fund to other government agencies, representatives of BARDA (Biomedical Advanced Research and Development Authority), NIH (National Institutes of Health), NIAID (National Institute for Allergies and Infectious Diseases) and DTRA (Defense Threat Reduction Agency), 15 CEO’s from some of the country’s leading biodefense and infectious diseases companies and a leading biodefense investment banking firm met yesterday during the JP Morgan Healthcare Conference here to discuss how best to facilitate the development and approval of products in this critical sector.  (All participants are listed below.)

Organized by FreeMind Group (www.freemindconsultants.com), specialists in helping companies and academic institutions in life sciences raise money from government agencies through grants and contracts, the wide-ranging discussion covered what federal agencies are doing to create greater transparency for their funding initiatives, communicate their individual projects to each other and encourage investment from the venture capital community.
Steve Brozak, president of WBB Securities LLC, a research and investment firm focusing on biotechnology, medical devices and specialty pharmaceuticals, launched the discussion, noting that “there must be more transparency in terms of what the government expects from the companies it will fund”—regarding milestones, results, and areas of  prioritization (such as what threats are in focus), both for prospective grantees and to give the venture capital community the security to invest in these companies.  

Public sector participants agreed—and see the need.  The number of applications for NIH’s SBIR funding alone has doubled since private sector money has withdrawn from early stage companies, many “in danger of going out of business”—and there was speculation that the success rate for these applications could plummet from its current 25 percent to below ten percent.  There is also pressure within the granting agencies to allow venture capital-funded companies to compete for available dollars, and it is possible a small percentage may be permitted. Funding for BARDA, which is dedicated to the development and purchase of necessary vaccines, drugs, therapies and diagnostic tools for public health medical emergencies and manages Project BioShield, has increased from $100 million in 2007 and 2008 to $305 million for this year.

The awareness has led to shorter applications for some grants and contracts, and in some cases, larger awards—notably in NIH’s RO1 programs—particularly where there is an academic/industry partnership.  Much information on the status of potential grants is now published on the individual agencies’ Web sites.   And a very new development is the creation of the Integrated National Biodefense Portfolio, a collaborative effort among BARDA, DTRA, NIH, NIAID and the Department of Defense to minimize duplication of projects and to monitor progress of all candidates in the portfolio.

“Government and industry are much closer collaborators in the biodefense sector than ever before,” said Ram May-Ron, Vice President of FreeMind.  “The efforts cited above and the sheer volume of information now being exchanged signals much more clarity of communication and bodes well for better and more targeted grants and contracts for important emerging science.”
Among other topics covered in the two-hour discussion:

  • intellectual property issues, particularly in the case of reagents
  • investigation of licensed drugs for off-label uses in response to bio-terror threats, to mitigate response time
  • using the NIAID’s 11 Centers of Excellence as incubators, rather than strictly as academic research sites.

In addition to Ram May-Ron and FreeMind’s chief analyst, Dr. Merav Geva, the roundtable included:

From the public sector:
  • Clare K. Schmitt, Ph.D., Deputy Director - Office of Biodefense Research Affairs, DMID/NIAID, NIH
  • Michael R. Schaefer, PhD, Regional Centers of Excellence Program Officer - Office of Biodefense Research Affairs, DMID-NIAID, NIH
  • Brian Reinhardt, CIV, Chemical and Biological Defense Directorate - DTRA
  • Gary L. Disbrow Ph.D., Deputy Director, Division of CBRN Countermeasures -BARDA, Assistant Secretary for Preparedness and Response ASPR--Department of Health and Human Services
Gregory Milman, Ph. D. , Director, Office for Innovation and Special Programs, Division of Extramural Activities - NIAID, NIH, DHHS.

From the private sector: 
  • Michael Eichberg, Director, Business Development - Achaogen
  • Patrick Flavin, Esq., JD - Advanced Life Sciences
  • Eric J. Patzer, Founder & President - Aridis Pharma
  • James L. Knighton, President & CEO - AvidBiotics
  • Michael Fonstein, PhD, CEO - Cleveland Biolabs
  • Lynn Stevenson, CEO - DesignMedix  
  • Steven Dong, PhD, Director of Drug Discovery and Development - Epiphany  Biosciences 
  • Richard Haiduck, Chief Business Officer - Implicit Biosciences
  • Steve Parkinson, President & CEO - Lakewood-Amedex
  • Jeff Meshulam, COO - Profectus BioSciences
  • Christopher J. Schaber, President & CEO - Soligenix
  • Joyce Sutcliffe, SVP, Biology - TetraPhase Pharmaceuticals
  • David Fanning, CEO - Theraclone Sciences
  • Steve Brozak, President - WBB Securities, LLC.

CONTACT: 
Tami Hamaway, FreeMind Group 617-648-0340  tami@freemindconsultants.com

 

 

28th JP Morgan Annual Healthcare Conference

January 12th, 2010

During the 28th JP Morgan Annual Healthcare Conference (H&Q) on January 2010 FreeMind's , VP Mr. Ram May-Ron will hold a presentation on "large scale Grants and Contracts from the NIH/DOD".

Industry and Academic Executives are cordially invited to hear and discuss the strategy employed in the securing of such funding.

Free entry through registration required; space is limited.

Register Now or contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at hannah@freemindconsultants.com

28th JP Morgan Annual Healthcare Conference

January 11-13, 2010

During the 28th JP Morgan Annual Healthcare Conference (H&Q) on January 2010 Mr. Ram May-Ron, VP of FreeMind Group will be holding strategic consultations with Industry Executives on trends at the NIH and DOD in 2010and discussions regarding specific projects.
All meetings will be held at the Handlery hotel (across from the Westin St. Francis Hotel).

Schedule a meeting now or contact Hannah Rosencweig at (617) 648-0340, ext. 220, or at hannah@freemindconsultants.com

Podcast

FreeMind Vice President, Ram May-Ron featured on the The Burrill Report' Biotechs Expand Their Financial Arsenal' (MP3 Podcast)

Texas Life Science Conference 2009, Houston, TX

November 13th, 2009

At the Texas Life Science Conference 2009, Houston, TX FreeMind's Vice President Ram May-Ron will take part at a Panel on: “Alternative Financing Resources”

Ram May-Ron, Vice President, FreeMind Group will be joined by:
William J. Kridel, Managing Director, Ferghana Partners;
Joyce Cramer, President, Epilepsy Therapy Project
Sjoerd Boomsma, Limburg Investment Bank and representative of the Texas CPRIT/ETF.

To schedule a meeting please contact Casey Levin at casey@freemindconsultants.com or at (617) 648-0340 ext. 216

 

BioFlorida’s 12th Annual Conference

November 5th, 2009

Ram May-Ron will hold a presentation and will participate in a panel at the BioFlorida’s 12th Annual Conference

Seminar: “Government Funding as a Financial Engine for Life Sciences”

Workshop: “Support for Emerging Companies”- Regulations and policies affecting entrepreneurs and growing bioscience companies with a focus on Florida’s critical needs.

Ram May-Ron, Vice President, FreeMind Group will be joined by:
Patrick Kelly Vice President, State Government Relations, Biotechnology Industry Organization
Ray Johnson, President, Cytonics, an emerging biotech, headquartered in Jupiter, Florida

To register please visit BioFlorida's website at: www.bioflorida.org

Indiana Health Industry Forum

 Indianapolis, IN.
Meetings with local emerging and mid-stage life sciences firms and academic research institutions.

Annual BIO Investor Forum, San Francisco, CA

 October 28 - 29, 2009

Ram May-Ron will hold two seminars at the Palace Hotel, San Francisco, CA, coincident with the Forum, on “Turning Grants & Contracts into a Multi-Million Source of Funding”

The seminars are FREE of charge.
Register Now or for further information please contact Casey Levin at (617) 648-0340, ext. 216 casey@freemindconsultants.com

Immediate Large Scale Grants & Contracts for Life Science Companies

October 27th 2009

FreeMind Group is pleased to invite you to a
special webinar focusing on the latest announcement of the Diabetes, Cancer, Bio-defense, Psychiatry, and Health Care Infrastructure programs, as well as other available mechanisms for funding


Presenter: Joel Knopf, Senior Consultant, FreeMind Group LLC

In the past few weeks NIH has issued several large scale funding opportunities, grants and contracts in different fields. The deadline for these opportunities is between Nov 2009 and Jan 2010 and they will cover advanced research and development activities in the fields of Bio-Defense, Diabetes, Cancer, Psychiatry, and Health Care Infrastructure. In this webinar, a FreeMind expert will discuss the diverse opportunities, the differences between a standard grant application and a large scale one, the challenges these complex applications pose, and the ways to overcome them. Additional issues to be covered include:

  • The challenges in assembling a complex and large scale application
  • NIH in the wake of the 'stimulus avalanche'
  • Short term/Large scale funding opportunities
  • Process for applying, requirements and limitations
  • How to maximize chances for success
  • Government funding as a strategic source of funding

The webinar is designed for experienced companies as well as for first-time submitters who wish to increase their success rates and the total amount of funding awarded.

Tuesday, October 27th at 1:30-2:30 PM EDT

The webinar is FREE of charge.
Register Now or for further information please contact Casey Levin at (617) 648-0340, ext. 216 casey@freemindconsultants.com

FreeMind is featured in the San Diego Business Journal

 FreeMind is featured in the San Diego Business Journal

 

Life Sciences Summit 2009

September 23rd, 2009

Please join FreeMind's Vice President, Ram May-Ron at the business workshop where he will be among the panelists speaking about alternative funding options.

Business Workshop
Alternative funding options
Even without the current economic environment, venture funding for early stage biotech companies is difficult. This session will focus on other ways to raise capital, many of which have the added benefit of being non-dilutive.

  • Ram May-Ron, Vice President, FreeMind Consultants

The Life Sciences Summit will take place on September 23-24, 2009 at the Hyatt Regency Long Island,1717 Motor Parkway, Hauppauge, New York, USA 11788
 

Register Now www.lifesciencessummit.org/2009/

For further information please contact Casey Levin at (617) 648-0340, ext. 216 casey@freemindconsultants.com

Government Funding for Infectious Diseases R&D Activities

July 28th, 2009

FreeMind Group and BIO are pleased to invite you to a special webinar focusing on the latest announcement of the NIAID programs, as well as other available mechanisms for funding through DOD, MITI, BARDA and others
Presenters: Ram May-Ron, Vice President
Merav Geva, PhD., Chief Analyst & Director of Professional Services
FreeMind Group LLC

Funding is available from different govt. sources to support R&D efforts for infectious diseases, ranging from the very beginning of exploratory research and all the way to final stage clinical testing. These mechanisms may often lead to future purchase opportunities and differ in focus and potential as well as in scope and in the appropriate presentation necessary for success. We will attempt to shed some light on available funding opportunities. In particular, we will touch upon:

  • NIAID - Funding opportunities for BioDefense R&D
  • Other government agencies' funding opportunities for infectious diseases related research
  • Application process, requirements and limitations, and the differences between the requirements of different agencies and mechanisms
  • How to maximize chances for success
  • Government funding as a strategic source of funding

The webinar is designed for experienced companies as well as for first-time submitters who wish to increase their success rates and the total amount of funding awarded.
 

Tuesday, July 28th at 1:00-2:00 PM EDT
 

The webinar is FREE of charge.
Register Now or contact Casey Levin at (617) 648-0340, ext. 216, or at casey@freemindconsultants.com

 

The process of on-line registration to grants.gov

July 1st, 2009

FreeMind Group and BIO are pleased to invite you to a special
tutorial webinar focusing on the process of on-line registration to grants.gov

Presenter: Mr. Joel Knopf, MSc, MBA, Senior Consultant, FreeMind Group LLC

  • Why registration is needed
  • Why register in advance
  • Registration timeline
  • Registration process
  • Detailed registration walk-through

The webinar is designed for experienced companies as well as for first-time submitters who wish to increase their success rates and the total amount of funding awarded.

To register please contact Casey Levin at casey@freemindconsultants.com or at (617) 648-0340 ext. 216

NIH Industry Focused RC3 Funding

July 14th, 2009

FreeMind Group and BIO are pleased to invite you to a 2nd tutorial webinar focusing on the recently announced NIH RC3 Commercially Oriented Funding Opportunity
Presenter: Mr. Joel Knopf, MSc, MBA, Senior Consultant, FreeMind Group LLC

Biomedical Research, Development and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) RFA-OD-09-008

  • How to maximize your chances for success
  • Scope and objectives of the program
  • Funding
  • Eligibility and requirements

The webinar is designed for experienced companies as well as for first-time submitters who wish to increase their success rates and the total amount of funding awarded.

Tuesday, July 14th at 3:00-4:00 PM EDT

The webinar is FREE of charge.
Register Now or for further information please contact Casey Levin at (617) 648-0340, ext. 216 casey@freemindconsultants.com